Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer

NCT00952497 is registered in ClinicalTrials.gov with ACT Biotech, Inc as lead sponsor.

NCT NCT00952497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00952497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer
Lead sponsor
ACT Biotech, Inc
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
January 31, 2012
Enrollment
48 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer